Clinical Trials Logo

Leptomeningeal Disease clinical trials

View clinical trials related to Leptomeningeal Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06417710 Recruiting - Clinical trials for Leptomeningeal Metastasis

Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis

NANO-LM
Start date: January 30, 2022
Phase:
Study type: Observational

The goal of this project is to develop and validate a reproducible scorecard for the neurological assessment of patients with leptomeningeal metastases that can be used in clinical trials including such patients, as well as in clinical practice.

NCT ID: NCT06146010 Recruiting - Clinical trials for Leptomeningeal Disease

Non Interventional German Leptomeningeal Disease Register

Start date: May 13, 2024
Phase:
Study type: Observational [Patient Registry]

The planned multicenter register is intended to create a database in the form of a cancer register on the incidence and course of disease in Germany of leptomeningeal disease, the therapeutic measures administered in the real world and the complications.

NCT ID: NCT05809752 Recruiting - Clinical trials for Triple Negative Breast Cancer

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

Start date: August 22, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment that can be given safely to Breast Cancer patients with Leptomeningeal Disease

NCT ID: NCT05800275 Recruiting - Clinical trials for Leptomeningeal Metastasis

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

ETIC-LM
Start date: December 18, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy of tucatinib and capecitabine in combination with intrathecal trastuzumab on overall survival rate at 12 months in HER2-positive metastatic breast cancer (MBC) patients with proven leptomeningeal evolution and requiring intrathecal therapy.

NCT ID: NCT05112549 Recruiting - Clinical trials for Leptomeningeal Disease

Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)

IT-PD1
Start date: October 12, 2021
Phase: Phase 1
Study type: Interventional

To determine the safety of intrathecal (IT) PD1 antibody for Intrathecal application of PD1 antibody in metastatic solid tumors with leptomeningeal disease of solid tumors.

NCT ID: NCT04588545 Recruiting - Clinical trials for HER2-positive Breast Cancer

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Start date: December 10, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find out if radiation therapy followed by intrathecal trastuzumab and pertuzumab is safe and will result in improved survival in HER2 positive breast cancer which has metastasized to the leptomeninges.

NCT ID: NCT02422641 Recruiting - Clinical trials for Metastatic Breast Cancer

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

Start date: May 2015
Phase: Phase 2
Study type: Interventional

Management of leptomeningeal disease (LMD) in patients with metastatic breast cancer is an area of unmet clinical need. High-dose methotrexate (HD-MTX) is known to have activity against breast cancer and in contrast to other systemic chemotherapeutics, it penetrates the blood brain barrier, targets areas of poor cerebrospinal fluid flow, may penetrate bulky leptomeningeal disease, and provide treatment to systemic disease burden. While two retrospective studies have suggested activity of HD-MTX in LMD in patients with breast cancer, no prospective data are available to inform its inclusion in treatment regimens. Thus, while HD-MTX is included in the NCCN Guidelines for LMD and while it is used to varying degrees in cancer centers across the nation, this is more representative of the lack of available therapies for LMD as opposed to strong evidence-based data. This phase II, prospective study will evaluate systemic, intravenous HD-MTX in breast cancer patients with leptomeningeal metastasis with or without brain parenchymal metastasis.